As pandemic restrictions begin to loosen in many communities across the country, patients with chronic lymphocytic leukemia (CLL) face greater uncertainty in this "new normal" due to their increased risk for contracting COVID-19 and a lower response rate to the vaccine.   On this episode, three clinicians discuss their experiences with difficult conversations on the relative risks and benefits around treatment decisions, engaging the entire cancer team in shared decision-making with patients, accessing emerging evidence and data in this rapidly evolving environment, and the potential impact of variant exposure on this unique patient population.   Guests: John N. Allan, MD Assistant Professor of Medicine Division of Hematology and Medical Oncology Weill Cornell Medicine New York, NY   Mark J. Fesler, MD Director, Bone Marrow Transplant Program, Associate Professor of Internal Medicine Division of Hematology and Oncology Saint Louis University St. Louis, MO   Susannah P. Friemel, MD  Owner/President Iowa Cancer Specialists, PC Davenport, IA    Related Content [VIDEO PODCAST] Ep 02: Myeloma Care Strategies & COVID-19 Trending Now in Cancer Care Resources Telehealth at Its Best: Transitioning a Comprehensive Psychosocial Program to a Virtual Format Telemedicine and Cancer Care: Today's Learnings for a Post-Pandemic World ACCC Telehealth Resources [PODCAST] Episode 28: Telehealth & Genetics During COVID-19 [PODCAST] Mini-Podcast: Staff Resiliency During COVID-19

Ver todos los episodios